The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: A single-center experience

Clinical Transplantation

Volumn 25, Issue 6, 2011, Pages 878-884

  Shirakawa, Hiroki ^a   Ishida, Hideki ^a   Shimizu, Tomokazu ^a   Omoto, Kazuya ^a   Iida, Shoichi ^a   Toki, Daisuke ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

ABO incompatible kidney transplantation; Anti CD20 antibody; Splenectomy

Indexed keywords

BASILIXIMAB; CD19 ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; DRUG DOSE REDUCTION; FEMALE; HISTOINCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLENECTOMY;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP INCOMPATIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROGNOSIS; SPLENECTOMY; TOKYO;

EID: 80052311553     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01384.x     Document Type: Article

References (19)

1. Tydén G, Kumlien G, Fehrmal I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003: 76: 730.
2. Toki D, Ishida H, Horita S et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009: 22: 447.
3. Saito K, Nawata M, Iwata S et al. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford) 2005: 44: 1462.
4. Solez K, Colvin RB, Racusen LC et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007: 7: 518.
5. Starzl TE, Marchioro TL, Holmes JH et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964: 55: 195.
6. Alexandre GP, De Bruyere M, Squifflet JP et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985: 19: 1989.
7. Takahashi K, Saito K, Thakahara S et al. Excellent long-term outcome of ABO-incompatible living kidney transplantation in Japan. Am J Transplant 2004: 4: 1089.
8. Malangoni MA, Dillon LD, Klamer TW et al. Factors influencing the risk of early and late serious infection in adults after splenectomy for trauma. Surgery 1984: 96: 775.
9. Alexander JW, First MR, Majeski JA et al. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984: 37: 467.
10. Segeve DL, Simpkins CE, Warren DS et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005: 5: 2570.
11. Ishida H, Furusawa M, Murakami T et al. Outcome of an ABO-incompatible renal transplant without splenectomy. Transpl Int 2002: 15: 56.
12. Shroder C, Azimzadeh AM, Wu G et al. Anti-CD20 treatment depletes B cells in blood and lymphatic tissue of cynomolgus monkey. Transplant Immunol 2003: 12: 19.
13. Tobinai K, Kobahashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Stufy Group. Ann Oncol 1998: 9: 527.
14. Genberg H, Hansson A, Wernerson A et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006: 6: 2418.
15. Fernández-Fresnedo G, Ramos MA, González-Pardo MC et al. B lymphopenia in uremia is related to accelated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000: 15: 502.
16. Martin-Malo A, Carracedo J, Ramirez R et al. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000: 11: 936.
17. Chikaraishi T, Sasaki H, Tsutsumi H et al. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab. Tranplant Proc 2008: 40: 3445.
18. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation:1.Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004: 77: 542.
19. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008: 20: 444.